Showing posts with label bone drug. Show all posts
Showing posts with label bone drug. Show all posts

Breast Cancer Treatment May Lead to Hip Fracture

http://health-care-org.blogspot.com/

Middle-aged breast cancer survivors face an increased risk for hip fractures, a condition normally uncommon in women younger than 70, a new study has found. Researchers at Northwestern University in Chicago say that this may be because early menopause caused by breast cancer treatment and the effects of breast cancer drugs could weaken the bones by the time women reach middle age. The finding came from a study of six women who had survived breast cancer and, in their early 50s, were being treated for hip fractures.

Most of the women did not have osteoporosis, but they did have lower-than-normal bone mineral density (osteopenia). This suggests that rapid changes in bone architecture caused by chemotherapy, early menopause and adjuvant breast cancer therapy may not be detected on a bone mineral density test, said Dr. Beatrice Edwards, an associate professor of medicine and orthopedic surgery and director of the bone health and osteoporosis program Northwestern University's Feinberg School of Medicine, who led the research.

The women had been diagnosed with early-stage breast cancer, and their treatments had included lumpectomy, radiation therapy and chemotherapy with cytoxan and adriamycin for one to four years before they broke a hip. All of the women were perimenopausal at the time of the fracture. In four of the women, their breast cancer had grown in response to estrogen, and their cancer therapy had included aromatase inhibitors to prevent their bodies from making estrogen. Recent research has linked aromatase inhibitors with possible bone loss in women.

You have read this article bone / bone drug / breast / breast cancer / cancer / Drug / health care / women with the title bone drug. You can bookmark this page URL http://aganaktismenoi-volos.blogspot.com/2011/02/breast-cancer-treatment-may-lead-to-hip.html. Thanks!

Bone Drug Zometa Flops Overall as Breast Cancer Treatment

http://health-care-org.blogspot.com/
The bone drug zoledronic acid, considered a potentially promising weapon against breast cancer recurrence, has flopped in a new study involving more than 3,360 patients. The drug, long used to combat bone loss from osteoporosis, did not appear to prevent breast cancer from returning or to boost disease free survival overall. British researchers presented the disappointing findings Thursday at the San Antonio Breast Cancer Symposium in Texas.

"As a whole, the study is negative," study author Dr. Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday news conference on the findings. "There is no overall difference in recurrence rates or survival rates, except in older patients, defined as more than five years after menopause." That was a possible bright spot in the results.

"In that population, there is a benefit," Coleman said. The older women had a 27 percent improvement in recurrence and a 29 percent improvement in overall survival over the five-year follow-up, compared to those who didn't get the drug. "There was tremendous hope that this [drug] approach would be a major leap forward," Coleman noted. "There have been other trials that suggest this is the case." In one previous study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer.
You have read this article bone drug / breast cancer / Drug / Zoledronic acid with the title bone drug. You can bookmark this page URL http://aganaktismenoi-volos.blogspot.com/2010/12/bone-drug-zometa-flops-overall-as.html. Thanks!